Ligand-targeted liposomal anticancer drugs - PubMed

Review

Ligand-targeted liposomal anticancer drugs

P Sapra et al. Prog Lipid Res. 2003 Sep.

Abstract

Antibody or ligand-mediated targeting of liposomal anticancer drugs to antigens expressed selectively or over-expressed on tumor cells is increasingly being recognized as an effective strategy for increasing the therapeutic indices of anticancer drugs. This review summarizes some recent advances in the field of ligand-targeted liposomes (LTLs) for the delivery of anticancer drugs. New approaches used in the design and optimization of LTLs is discussed and the advantages and potential problems associated with their therapeutic applications are described. New technologies are widening the spectrum of ligands available for targeting and are allowing choices to be made regarding affinity, internalization and size. The time is rapidly approaching where we will see translation of anticancer drugs entrapped in LTLs to the clinic.

Similar articles

• Tumor-directed targeting of liposomes.

  Park YS. Park YS. Biosci Rep. 2002 Apr;22(2):267-81. doi: 10.1023/a:1020190606757. Biosci Rep. 2002. PMID: 12428904 Review.

• Ligand-targeted liposomes for cancer treatment.

  Sapra P, Tyagi P, Allen TM. Sapra P, et al. Curr Drug Deliv. 2005 Oct;2(4):369-81. doi: 10.2174/156720105774370159. Curr Drug Deliv. 2005. PMID: 16305440 Review.

• Recent advances in tumor vasculature targeting using liposomal drug delivery systems.

  Abu Lila AS, Ishida T, Kiwada H. Abu Lila AS, et al. Expert Opin Drug Deliv. 2009 Dec;6(12):1297-309. doi: 10.1517/17425240903289928. Expert Opin Drug Deliv. 2009. PMID: 19780711 Review.

• Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells.

  Mamot C, Drummond DC, Greiser U, Hong K, Kirpotin DB, Marks JD, Park JW. Mamot C, et al. Cancer Res. 2003 Jun 15;63(12):3154-61. Cancer Res. 2003. PMID: 12810643

• Towards clinical translation of ligand-functionalized liposomes in targeted cancer therapy: Challenges and opportunities.

  Belfiore L, Saunders DN, Ranson M, Thurecht KJ, Storm G, Vine KL. Belfiore L, et al. J Control Release. 2018 May 10;277:1-13. doi: 10.1016/j.jconrel.2018.02.040. Epub 2018 Mar 1. J Control Release. 2018. PMID: 29501721 Review.

Cited by

• Liposomal Nanomedicine: Applications for Drug Delivery in Cancer Therapy.

  Rommasi F, Esfandiari N. Rommasi F, et al. Nanoscale Res Lett. 2021 May 25;16(1):95. doi: 10.1186/s11671-021-03553-8. Nanoscale Res Lett. 2021. PMID: 34032937 Free PMC article. Review.

• Toward a magic or imaginary bullet? Ligands for drug targeting to cancer cells: principles, hopes, and challenges.

  Toporkiewicz M, Meissner J, Matusewicz L, Czogalla A, Sikorski AF. Toporkiewicz M, et al. Int J Nanomedicine. 2015 Feb 17;10:1399-414. doi: 10.2147/IJN.S74514. eCollection 2015. Int J Nanomedicine. 2015. PMID: 25733832 Free PMC article. Review.

• Targeting and internalization of sterically stabilized liposome modified with ZCH-4-2E8.

  Zhang J, Tang Y, Shen H, Qian B. Zhang J, et al. J Huazhong Univ Sci Technolog Med Sci. 2009 Jun;29(3):273-80. doi: 10.1007/s11596-009-0302-2. Epub 2009 Jun 10. J Huazhong Univ Sci Technolog Med Sci. 2009. PMID: 19513605

• Exploiting lipid raft transport with membrane targeted nanoparticles: a strategy for cytosolic drug delivery.

  Partlow KC, Lanza GM, Wickline SA. Partlow KC, et al. Biomaterials. 2008 Aug;29(23):3367-75. doi: 10.1016/j.biomaterials.2008.04.030. Epub 2008 May 16. Biomaterials. 2008. PMID: 18485474 Free PMC article.

• Challenging the future of siRNA therapeutics against cancer: the crucial role of nanotechnology.

  Gomes-da-Silva LC, Simões S, Moreira JN. Gomes-da-Silva LC, et al. Cell Mol Life Sci. 2014 Apr;71(8):1417-38. doi: 10.1007/s00018-013-1502-2. Epub 2013 Nov 13. Cell Mol Life Sci. 2014. PMID: 24221135 Free PMC article. Review.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Elsevier Science

• Other Literature Sources

  • The Lens - Patent Citations Database